Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Sep 08, 2022 9:32am
78 Views
Post# 34949037

RE:RE:RE:Brokered Private Placement

RE:RE:RE:Brokered Private PlacementMetzger:  I was wondering when you were going to finally snap (again).  Lately you have put on a brave face and been quite supportive of "Lee and his merry men" .  You have been adament that the Arbitration is a slam dunck in Replicel's favour. I was beginning to admire your "glass half full" attitude as compared to my "glass half empty" stance on what is going on.  This last post is more along the lines of most of us here that are fed up with this.

Bellend:  Good find on the International Center For Dispute Resolutions document. The first question that comes to mind after reading this document is why are they keeping us non insiders in the dark as to where they are in this process.  It obviously has a very detailed timeline that plays out and we are rapidly coming to the deadline which is Oct. 18th.  With so much on the line with this Arbitration we as shareholders of a public company are entitled to be informed.  The CSA has very strict requirements for disclosure of any financial or legal developments of a public company.   Replicel management (Lee Buckler) has chosen to ignore this regulation for some reason....why?
<< Previous
Bullboard Posts
Next >>